The Latest Analyst Ratings for Immunovant
Portfolio Pulse from Benzinga Insights
Immunovant (NASDAQ:IMVT) has received mostly bullish ratings from analysts in the last quarter, with no bearish or indifferent ratings. The average 12-month price target for the stock, according to 14 analysts, is $34.14, which has increased by 16.4% over the past month.
October 09, 2023 | 4:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Immunovant has received positive analyst ratings, which could boost investor confidence and potentially drive the stock price up in the short term.
Analyst ratings often influence investor sentiment. In this case, the predominantly bullish ratings for Immunovant indicate a positive outlook for the company, which could lead to increased investor interest and a potential rise in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100